197 related articles for article (PubMed ID: 37891368)
1. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
[TBL] [Abstract][Full Text] [Related]
2. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
5. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
[TBL] [Abstract][Full Text] [Related]
6. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.
Shouse G; de Necochea-Campion R; Mirshahidi S; Liu X; Chen CS
Oncotarget; 2016 Sep; 7(38):61081-61092. PubMed ID: 27531894
[TBL] [Abstract][Full Text] [Related]
7. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.
Frett B; Stephens KE; Koss B; Melnyk S; Farrar J; Saha D; Roy Choudhury S
Cancer Sci; 2024 Mar; 115(3):963-973. PubMed ID: 38226414
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
9. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
Tubío-Santamaría N; Jayavelu AK; Schnoeder TM; Eifert T; Hsu CJ; Perner F; Zhang Q; Wenge DV; Hansen FM; Kirkpatrick JM; Jyotsana N; Lane SW; von Eyss B; Deshpande AJ; Kühn MWM; Schwaller J; Cammann C; Seifert U; Ebstein F; Krüger E; Hochhaus A; Heuser M; Ori A; Mann M; Armstrong SA; Heidel FH
Mol Cancer; 2023 Dec; 22(1):196. PubMed ID: 38049829
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
11. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
[TBL] [Abstract][Full Text] [Related]
12. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
13. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract][Full Text] [Related]
14. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
[TBL] [Abstract][Full Text] [Related]
15. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
16. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.
Casado P; Rio-Machin A; Miettinen JJ; Bewicke-Copley F; Rouault-Pierre K; Krizsan S; Parsons A; Rajeeve V; Miraki-Moud F; Taussig DC; Bödör C; Gribben J; Heckman C; Fitzgibbon J; Cutillas PR
Signal Transduct Target Ther; 2023 Feb; 8(1):80. PubMed ID: 36843114
[TBL] [Abstract][Full Text] [Related]
17. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
19. A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia.
Harada T; Heshmati Y; Kalfon J; Perez MW; Xavier Ferrucio J; Ewers J; Hubbell Engler B; Kossenkov A; Ellegast JM; Yi JS; Bowker A; Zhu Q; Eagle K; Liu T; Kai Y; Dempster JM; Kugener G; Wickramasinghe J; Herbert ZT; Li CH; Vrabič Koren J; Weinstock DM; Paralkar VR; Nabet B; Lin CY; Dharia NV; Stegmaier K; Orkin SH; Pimkin M
Genes Dev; 2022 Mar; 36(5-6):368-389. PubMed ID: 35301220
[TBL] [Abstract][Full Text] [Related]
20. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
Faber J; Krivtsov AV; Stubbs MC; Wright R; Davis TN; van den Heuvel-Eibrink M; Zwaan CM; Kung AL; Armstrong SA
Blood; 2009 Mar; 113(11):2375-85. PubMed ID: 19056693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
